GlassScriptPhysician profile
Kim Almodovar
NPI 1831160316
$3,311.13
in general payments reported to CMS, 2019-2025
19 companies · $596 in 2025
The $596 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $304 · 2021: $657 · 2022: $352 · 2023: $393 · 2024: $481 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,470.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $921.68 | 2019-2025 | Skyrizi, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $758.06 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $437.32 | 2020-2025 | Stelara, Tremfya, Simponi |
| Merck Sharp & Dohme LLC | $202.78 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $198.04 | 2019-2025 | Ocaliva |
| Gilead Sciences, INC. | $187.85 | 2019-2022 | |
| Qol Medical, LLC | $187.40 | 2023-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $128.11 | 2024 | Rezdiffra, Resmetirom |
| Celgene Corporation | $53.57 | 2022 | |
| Ironwood Pharmaceuticals, INC | $49.94 | 2021 | |
| Shire North American Group INC | $32.56 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $30.06 | 2025 | Dupixent |
| Capsovision, INC. | $23.18 | 2023 | Capsocam Plus |
| Novo Nordisk INC | $20.12 | 2025 | Wegovy |
| Medtronic, INC. | $19.54 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $17.25 | 2021 | |
| Boston Scientific Corporation | $16.12 | 2023 | Wavewriter Alpha Prime 16 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.54 | 2019 | |
| Shionogi INC | $12.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Almodovar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.